Evolus (NASDAQ:EOLS) Sets New 12-Month High – Time to Buy?

Shares of Evolus, Inc. (NASDAQ:EOLS) hit a new 52-week high during trading on Monday . The company traded as high as $9.15 and last traded at $9.06, with a volume of 618548 shares changing hands. The stock had previously closed at $8.88.

Wall Street Analysts Forecast Growth

EOLS has been the topic of a number of recent research reports. BTIG Research reaffirmed a “buy” rating and issued a $13.00 target price on shares of Evolus in a research report on Wednesday, June 17th. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Tuesday, August 25th. Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.50.

Evolus Stock Performance

The stock has a 50-day simple moving average of $7.14 and a two-hundred day simple moving average of $5.99. The firm has a market cap of $599.73 million, a PE ratio of -17.46 and a beta of 1.35.

Institutional Trading of Evolus

A number of hedge funds and other institutional investors have recently bought and sold shares of EOLS. Rhumbline Advisers raised its stake in shares of Evolus by 2.0% in the second quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock worth $784,000 after buying an additional 1,657 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Evolus by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after acquiring an additional 1,838 shares during the period. Invesco Ltd. increased its holdings in Evolus by 7.5% in the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after acquiring an additional 2,383 shares in the last quarter. California State Teachers Retirement System increased its holdings in Evolus by 79.9% in the 2nd quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock worth $38,000 after acquiring an additional 2,423 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after acquiring an additional 2,837 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.